{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:24:03Z","timestamp":1790663043937,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Srl, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In this study, we evaluated the presence of residual disease in patients with axial spondyloarthritis (axSpA) in remission\/low disease activity (LDA) status. This cross-sectional post-hoc analysis of the QUASAR study involving 23 rheumatology centres across Italy included adults with axSpA classified according to the Assessment of SpondyloArthritis International Society criteria. Patients with inactive disease (score &lt; 1.3) or at least LDA status (score &lt; 2.1) at baseline visit according to Ankylosing Spondylitis Disease Activity Score were investigated to evaluate how residual disease activity impacts patients\u2019 quality of life. They were assessed using the Ankylosing Spondylitis Quality of Life (ASQoL) and EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaires. This study included 480 patients with axSpA (mean age, 47.5 \u00b1 12.9 years, 64% male). In total, 123 patients (25.6%) had inactive disease and 262 (54.6%) had at least LDA. Using the ASQoL, ranges of 10\u201325% and 20\u201340% of patients with inactive disease and with LDA status, respectively, experienced tiredness\/fatigue. Despite being classified with inactive disease, 48.8% of patients reported light pain\/discomfort according to the EQ-5D-5L, with 4.1% reporting moderate pain\/discomfort, whereas 55.7% of patients with LDA reported light pain\/discomfort and 13% had moderate pain\/discomfort. Using the ASQoL questionnaire, in patients with at least LDA, a higher proportion of women compared with males and a higher proportion of patients &gt; 48 years of age (vs. patients \u2264 48 years) experienced tiredness. In this post-hoc analysis, \u226525% of axSpA patients in remission\/LDA status were still burdened by residual disease, mainly characterised by pain and fatigue.<\/jats:p>","DOI":"10.3390\/jcm11123553","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T04:39:55Z","timestamp":1655786395000},"page":"3553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-1110","authenticated-orcid":false,"given":"Salvatore","family":"D\u2019Angelo","sequence":"first","affiliation":[{"name":"Rheumatology Department of Lucania, San Carlo Hospital of Potenza, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universit\u00e0 di Modena and Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Marando","sequence":"additional","affiliation":[{"name":"AbbVie Srl, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2621","authenticated-orcid":false,"given":"Giuliana","family":"Gualberti","sequence":"additional","affiliation":[{"name":"AbbVie Srl, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Novelli","sequence":"additional","affiliation":[{"name":"AbbVie Srl, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3310-5541","authenticated-orcid":false,"given":"Giacomo","family":"Curradi","sequence":"additional","affiliation":[{"name":"AbbVie Srl, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[{"name":"National Research Council\u2014Institute of Clinical Physiology (CNR-IFC), 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Pitino","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology (IFC-CNR), 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine-DIMED, University of Padova, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-5902","authenticated-orcid":false,"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[{"name":"Rheumatology, Humanitas San Pio X, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The Development of Assessment of SpondyloArthritis International Society Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of Diagnostic Criteria for Ankylosing Spondylitis. A Proposal for Modification of the New York Criteria","volume":"27","author":"Valkenburg","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102703","DOI":"10.1016\/j.autrev.2020.102703","article-title":"Do We Believe in Non-Radiographic Axial Spondyloarthritis? A Debate","volume":"20","author":"Ortolan","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4081\/reumatismo.2021.1367","article-title":"The Italian Society for Rheumatology Recommendations for the Management of Axial Spondyloarthritis","volume":"73","author":"Manara","year":"2021","journal-title":"Reumatismo"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/ITT.S259126","article-title":"Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis","volume":"10","author":"Atzeni","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-019-1812-3","article-title":"The Need for Comparative Data in Spondyloarthritis","volume":"21","author":"Choy","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00296-018-4201-3","article-title":"Residual Symptoms and Disease Burden among Patients with Psoriatic Arthritis: Is a New Disease Activity Index Required?","volume":"39","author":"Kilic","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kex183","article-title":"Residual Disease Activity in Psoriatic Arthritis: Discordance between the Rheumatologist\u2019s Opinion and Minimal Disease Activity Measurement","volume":"57","author":"Turina","year":"2018","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e016619","DOI":"10.1136\/bmjopen-2017-016619","article-title":"Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from a Prospective, Observational, Biological Treatment Registry","volume":"7","author":"Rahman","year":"2017","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-Endorsed Disease Activity Score (ASDAS) in Patients with Ankylosing Spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 Update of the Nomenclature for Disease Activity States","volume":"77","author":"Machado","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3899\/jrheum.200934","article-title":"Residual Disease Burden in Patients With Axial Spondyloarthritis and Psoriatic Arthritis Despite Low Disease Activity States in a Multiethnic Asian Population","volume":"48","author":"Liu","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_15","first-page":"748","article-title":"Observational Study on the QUality of Life of Italian Axial SpondyloARthritis Patients (QUASAR): Baseline Data","volume":"37","author":"Gilio","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.55563\/clinexprheumatol\/dz0xrd","article-title":"Quality of Life and Therapeutic Management of Axial Spondyloarthritis Patients in Italy: A 12-Month Prospective Observational Study","volume":"39","author":"Malavolta","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_17","first-page":"2286","article-title":"A New Approach to Defining Disease Status in Ankylosing Spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: A Quality of Life Instrument Specific to Ankylosing Spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"EuroQol Group (1990). A New Facility for the Measurement of Health-Related Quality of Life. Health Policy, 16, 199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10067-015-3035-6","article-title":"The Prevalence of Severe Fatigue in Rheumatic Diseases: An International Study","volume":"35","author":"Overman","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7525-5-7","article-title":"Translation and Validation of Non-English Versions of the Ankylosing Spondylitis Quality of Life (ASQOL) Questionnaire","volume":"5","author":"Doward","year":"2007","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Brooks, R., Rabin, R., and de Charro, F. (2003). Producing Other Language Versions of the EQ-5D. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the EuroQol BIOMED Research Programme, Springer.","DOI":"10.1007\/978-94-017-0233-1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s11136-012-0318-0","article-title":"Comparing the Performance of the Standard EQ-5D 3L with the New Version EQ-5D 5L in Patients with Chronic Hepatic Diseases","volume":"22","author":"Scalone","year":"2016","journal-title":"Qual. Life Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1093\/rheumatology\/keaa527","article-title":"Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-Analysis","volume":"59","author":"Ortolan","year":"2020","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating Axial Spondyloarthritis and Peripheral Spondyloarthritis, Especially Psoriatic Arthritis, to Target: 2017 Update of Recommendations by an International Task Force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of Comorbidities in Spondyloarthritis Including Psoriatic Arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3899\/jrheum.150463","article-title":"Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort","volume":"42","author":"Bedaiwi","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42358-018-0040-x","article-title":"Factors Associated with ASDAS Remission in a Long-Term Study of Ankylosing Spondylitis Patients under Tumor Necrosis Factor Inhibitors","volume":"58","author":"Shimabuco","year":"2018","journal-title":"Adv. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3899\/jrheum.151101","article-title":"Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin","volume":"43","author":"Marin","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","article-title":"Residual Disease Activity and Treatment Adjustments in Psoriatic Arthritis in Current Clinical Practice","volume":"19","author":"Fluri","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.200121","article-title":"Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-Recommended Next Steps","volume":"96","author":"Tillett","year":"2020","journal-title":"J. Rheumatol. Suppl."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/12\/3553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:35:46Z","timestamp":1760139346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/12\/3553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11123553"],"URL":"https:\/\/doi.org\/10.3390\/jcm11123553","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}